Neuro endocrine cancer tell me about it
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Reviewed by Dr. Chris Apfel, MD/PhD (UCSF)
Neuroendocrine Cancer: Educational Overview
I'd be happy to help you understand neuroendocrine cancer better. Let me explain what it is and what you should know.
What is Neuroendocrine Cancer?
Neuroendocrine cancer develops from neuroendocrine cells—special cells found throughout your body that produce hormones and help control body functions. These cells are found in many organs, including:
- Lungs (most common site)
- Pancreas
- Gastrointestinal tract (stomach, intestines)
- Thyroid
- Adrenal glands
When these cells grow abnormally and form tumors, they're called neuroendocrine tumors (NETs).
Key Characteristics
How they behave:
- Some grow slowly (low-grade/well-differentiated)
- Others grow faster (high-grade/poorly differentiated)
- They can produce excess hormones, causing specific symptoms
Common symptoms depend on location:
- Flushing or facial redness
- Diarrhea
- Abdominal pain or cramping
- Weight changes
- Fatigue
- Heart palpitations (in some cases)
Diagnosis & Testing
Your healthcare team typically uses:
- Imaging tests (CT, MRI, PET scans)
- Blood tests to measure hormone levels
- Biopsy to confirm diagnosis and grade the tumor
- Genetic testing in some cases
Treatment Approaches
According to NCCN Guidelines and American Cancer Society recommendations, treatment depends on:
- Location of the tumor
- Grade (how fast it's growing)
- Stage (how far it has spread)
- Hormone production (whether it's causing symptoms)
General treatment categories include:
- Surgery (when possible)
- Somatostatin analogs (medications that slow growth and manage symptoms)
- Chemotherapy (for higher-grade tumors)
- Targeted therapies (for specific genetic mutations)
- Immunotherapy (in certain cases)
- Radiation therapy (for specific situations)
Important Questions to Ask Your Oncologist
Since neuroendocrine cancer is complex and treatment is highly individualized, consider asking:
- What is the grade and stage of my tumor, and what does that mean for my prognosis?
- Where exactly is my tumor located, and has it spread?
- What are my treatment options, and which do you recommend for my specific situation?
- Are there clinical trials available for my type of neuroendocrine cancer?
- Should I have genetic testing, and if so, what mutations are you looking for?
- How will we monitor my tumor and treatment response over time?
- What support services are available (nutrition, symptom management, mental health)?
Where to Learn More
For authoritative information, I recommend:
- NCCN Guidelines (nccn.org) - comprehensive treatment recommendations
- American Cancer Society (cancer.org) - patient-friendly information
- National Cancer Institute (cancer.gov) - detailed medical information
- Neuroendocrine and Carcinoid Tumor Society (netcancer.org) - NET-specific resources
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Would you like me to explain any specific aspect of neuroendocrine cancer in more detail, or help you prepare questions for your care team?
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Have your records handy? Upload them for a deeper, personalized analysis →
Related Questions
Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...
TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...
TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya
It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...
TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2